After receiving positive interim data from a European trial of its Vercise deep-brain stimulation device, Boston Scientific (BSX) has begun a trial in the U.S.
The Vercise deep-brain stimulator is designed to boost motor function in patients suffering from Parkinson’s, a degenerative neurological condition. Early results from a study involving 40 Parkinson’s patients treated with Vercise in Europe revealed that after six months 60% of the study’s participants displayed motor function score improvements, MassDevice notes.
The company has implanted the device in the first patient in its U.S. trial in California.
Data on the European trial has been published at the International Congress of Parkinson’s Disease & Movement Disorders held in Sydney, Australia.
In January, Boston Scientific announced that it would lay off 1,000 workers in order to save between $100 million and $115 million in annual costs.
Shares of Boston Scientific fell about 1% in Tuesday morning trading.